Hair growth supplement capsules and bottles
Hair growth supplements occupy a lucrative middle ground between food and medicine — subject to far less regulatory scrutiny than drugs, but routinely marketed with clinical-sounding language that implies pharmaceutical-grade evidence.

Walk into a pharmacy or open Instagram and the pitch is everywhere: Nutrafol, Viviscal, and a shelf of biotin-forward hair gummies claiming to be “clinically proven” to regrow thinning hair. The price points run to $80–$90 a month. The language borrows from drug trials — “randomized,” “double-blind,” “statistically significant.” The before-and-afters show real results.

The evidence behind these products is real but systematically overstated. There are trials. They have design problems. And the products are consistently benchmarked against placebo rather than against minoxidil or finasteride — the actual standard of care — so the comparison that would actually matter to someone deciding between a supplement and a drug is never made.

Part of a Series

This article is part of our Hair Loss: Marketing or Science? series, examining the evidence behind popular treatments and ingredients.

What Is Actually in These Supplements

The formulations differ, but the category shares a core approach: combining several ingredients with individual mechanistic rationales into a proprietary blend. Key actives across leading brands include:

Individually, some of these ingredients have independent evidence threads — though nearly always in deficiency contexts or for mechanisms not specific to the scalp. The combination-product framing makes it impossible to attribute results to any single ingredient, a design problem that runs through the entire supplement literature.

The Claim

“Clinically proven to promote visibly thicker, stronger, faster-growing hair — powered by a multi-targeted formula that addresses the root causes of thinning.”

(Composite representative claim; reflects language used across Nutrafol, Viviscal, and biotin gummy marketing materials.)

The Clinical-Trial Problem

There are real trials. The Nutrafol women's formula has been tested in a randomized, double-blind, placebo-controlled 6-month study that reported statistically significant improvements in hair growth, volume, and thickness vs. placebo. A follow-up RCT in perimenopausal, menopausal, and postmenopausal women showed significantly increased vellus hair counts at day 180 vs. placebo. Viviscal similarly has multisite, double-blind, placebo-controlled trial data showing improvements in terminal hair count, and a 6-month placebo-controlled trial in men with thinning hair reporting decreased shedding and increased growth.

The trials exist. But several design features recur across the supplement literature that constrain how much weight those results should carry:

The Biotin Myth in Particular

Biotin warrants its own paragraph because it is the ingredient most broadly sold as a hair supplement and has the weakest evidence base for people who are not deficient. As established in our full biotin review, the evidence for biotin supplementation benefiting hair is essentially confined to people with genuine biotin deficiency — a condition that is rare in a healthy adult eating a varied diet. For the general population, the body already has as much biotin as it needs, and adding more does not drive additional hair growth.

The reason biotin persists in the category is partly marketing momentum and partly the absence of meaningful regulatory gatekeeping: a supplement cannot legally claim to treat hair loss, but it can claim to “support healthy hair,” and the consumer conflates the two. High-dose biotin (above 5,000 mcg) also interferes with thyroid and cardiac biomarker assays, a real clinical concern worth knowing.

How This Compares to the Standard of Care

The benchmark that supplement marketing avoids is the one that matters: head-to-head against the treatments with genuine evidence. Minoxidil and finasteride are backed by large, replicated, independent randomized controlled trials, regulatory review, and decades of real-world use. The available supplement evidence — small, manufacturer-funded, placebo-controlled only — is in a different evidentiary category.

Treatment Best Human Evidence Independent of Manufacturer? Benchmarked vs. Drug? Regulatory Status
Minoxidil Multiple large RCTs; decades of use Yes — FDA-approved for hair loss
Finasteride Multiple large RCTs in male pattern loss Yes — FDA-approved (men)
Nutrafol Small-to-medium manufacturer-funded RCTs vs. placebo No No Dietary supplement (not a drug)
Viviscal Small manufacturer-funded RCTs vs. placebo No No Dietary supplement (not a drug)
Biotin (no deficiency) No controlled evidence of benefit N/A No Dietary supplement

What the Evidence Actually Shows

Hair growth supplements like Nutrafol and Viviscal have real trial data showing they outperform placebo on hair-count and shedding measures. But that evidence is consistently manufacturer-funded, tested against placebo rather than against drugs, limited to small samples, and often reliant on subjective endpoints. Independent replication is absent. Biotin specifically offers no benefit to people who are not deficient — which is most adults. “Clinically proven” in this context means “better than nothing” in a small trial the company paid for; it does not mean equivalent to, or a substitute for, the drugs with replicated evidence.

Verdict & Practical Implications

Verdict: Claim Overstated

The “clinically proven” claim is overstated. There is real but limited evidence that certain supplements have some effect on hair counts — Nutrafol and Viviscal more so than plain biotin — but it comes from trials designed and funded by the manufacturers, tested only against placebo, and not yet independently replicated. The effect size relative to minoxidil or finasteride is unknown. Evidence rating: 3/5 — real trials with real limitations.

The practical implication depends on the individual. For someone who cannot or will not use minoxidil or a 5-alpha reductase inhibitor, a well-formulated supplement represents a modest, low-risk intervention on plausible mechanistic grounds. The first priority, though, should be ruling out treatable underlying causes — iron deficiency in particular is common and highly responsive to correction — before spending $80 a month on a supplement. And biotin alone is not the answer for anyone who eats a normal diet.

References & Further Reading